Eli Lilly (NYSE:LLY) has received mixed analyst ratings over the last quarter, with 8 analysts offering varying opinions. The average 12-month price target is $635.88, with a high of $722.00 and a low of $535.00, marking a 2.4% decrease from the previous average target of $651.50. Analysts from Barclays, Daiwa Capital, Truist Securities, Cantor Fitzgerald, Deutsche Bank, and Morgan Stanley have provided updates, with some maintaining and others raising their price targets. Eli Lilly's financial performance shows strong revenue growth but below-average net margin, ROE, and ROA, and a high debt-to-equity ratio.